期刊文献+

磁性纳米材料:化学合成、功能化与生物医学应用 被引量:15

Magnetic Nanoparticles: Chemical Synthesis, Functionalization and Biomedical Applications
下载PDF
导出
摘要 磁性纳米材料,由于其独特的磁学性能、小尺寸效应,被广泛应用于生物医学领域.本文总结了磁性纳米材料的化学设计与合成、表面功能化方法,及其在核磁共振成像、磁控治疗、磁热疗和生物分离等生物医学领域的应用进展. Magnetic nanoparticles that have magnetic properties and other functionalities, have a broad application prospects in many fields, especially in biomedicine and bioengineering. In this review, chemical design and synthesis, as well as the surface functional strategy of magnetic nanoparticles are presented. The biomedical applications, such as magnetic resonance imaging, magnetic-controlled therapy, magnetic hyperthermia, and bio-separation, are also discussed.
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2013年第10期903-917,共15页 Progress In Biochemistry and Biophysics
基金 国家自然科学基金(51125001 51172005 90922033) 国家自然科学基金外国青年学者研究基金(51250110078) 国家教育部博士点专项基金(20120001110078) 北京大学工学院-医学部交叉学科联合研究种子基金资助项目~~
关键词 磁性纳米材料 合成 功能化 生物医学应用 magnetic nanoparticles, synthesis, functionalization, biomedical application
  • 相关文献

参考文献2

二级参考文献37

  • 1Jianfang QIAN,Aiqiang DONG,Minjian KONG,Zhiyuan MA,Junqiang FAN,Guanyu JIANG.Suppression of Type 1 Insulin-like Growth Factor Receptor Expression by Small Interfering RNA Inhibits A549 Human Lung Cancer Cell Invasion in vitro and Metastasis in Xenograft Nude Mice[J].Acta Biochimica et Biophysica Sinica,2007,39(2):137-147. 被引量:9
  • 2Szakacs, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5, 219-234.
  • 3Kirkin, V.; Joos, S.; Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta-Mol. Cell Res. 2004, 1644,229-249.
  • 4Kruh, G. D. Introduction to resistance to anticancer agents. Oncogene 2003, 22, 7262-7264.
  • 5Calderwood, S. K.; Khaleque, M. A.; Sawyer, D. B.; Ciocca, D. R. Heat shock proteins in cancer: Chaperones of tumorigenesis. Trends Biochem. Sci. 2006,31, 164-172.
  • 6Duhem, C.; Ries, F.; Dicato, M. What does multidrug resistance (MDR) expression mean in the clinic. Oncologist 1996,1,151-158.
  • 7Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000,11,265-283.
  • 8Ferry, D. R.; Traunecker, H.; Kerr, D. J. Clinical trials of P-gJycoprotein reversal in solid tumours. Eur. J. Cancer 1996, 32A, 1070-1081.
  • 9Rowinsky, E. K.; Smith, L.; Wang, Y. M.; Chaturvedi, P.; Villalona, M.; Campbell, E.; Aylesworth, C.; Eckhardt, S. G.; Hammond, L.; Kraynak, M., et al. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDRI and MRP. J. Clin. Oncol. 1998,16,2964-2976.
  • 10Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev. 2008, 34, 592-602.

共引文献10

同被引文献224

引证文献15

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部